TYRA实时信号 | 通过Getagraph.com最大化利润

购买 110355 min ago

@ $19.02

发出时间: 13 Feb 2024 @ 01:36

回报率: -17.61%

上一信号: Feb 12 - 22:39

上一信号: 出售

回报率: -0.94 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer...

Stats
今日成交量	76 678.00
平均成交量	144 765
市值	823.05M
EPS	$0 ( 2024-03-27 )
下一个收益日期	( $-0.460 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.67
ATR14	$0.0350 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Fuhrman Alan	Buy	932	Common Stock
2024-03-15	Tada Hiroomi	Buy	1 968	Common Stock
2024-03-15	Harris Todd	Buy	1 880	Common Stock
2024-03-11	Bensen Daniel	Sell	200	Common Stock
2024-03-06	Bensen Daniel	Sell	1 733	Common Stock

INSIDER POWER
85.24
Last 100 transactions
Buy: 6 273 982 \| Sell: 603 690

音量相关性

長: -0.35 (neutral)

短: -0.78 (moderate negative)

Signal:(47.628) Neutral

Tyra Biosciences, Inc. 相关性

10 最正相关
DRNA	0.954
SUMO	0.939
IOAC	0.936
OCSL	0.935
IRMD	0.932
CMPI	0.922
XM	0.921
ALBO	0.92
SLMBP	0.919
PRAA	0.915

10 最负相关
GMII	-0.933
WASH	-0.921
AFYA	-0.913
EAR	-0.897
TRMK	-0.897
XPDI	-0.894
GOOD	-0.893
ALXO	-0.888
TUEM	-0.888
AVIR	-0.884

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Tyra Biosciences, Inc. 相关性 - 货币/商品

-0.09
( neutral )

0.15
( neutral )

0.00
( neutral )

-0.02
( neutral )

0.41
( neutral )

-0.56
( weak negative )

Tyra Biosciences, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-353 000 (0.00 %)
EPS:	$-1.620

FY	2023
营收:	$0
毛利润:	$-353 000 (0.00 %)
EPS:	$-1.620

FY	2022
营收:	$0
毛利润:	$-296 000 (0.00 %)
EPS:	$-1.230

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.910

Financial Reports:

No articles found.

Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

实时更新： Tyra Biosciences, Inc. [TYRA]

Upcoming Earnings Alert